The estimated Net Worth of Catherine Larue is at least $615 dollars as of 31 January 2023. Catherine Larue owns over 438 units of Quotient Ltd stock worth over $615 and over the last 4 years he sold QTNT stock worth over $0. In addition, he makes $0 as Independent Director at Quotient Ltd.
Catherine has made over 10 trades of the Quotient Ltd stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 438 units of QTNT stock worth $166 on 31 January 2023.
The largest trade he's ever made was exercising 6,917 units of Quotient Ltd stock on 31 October 2022 worth over $2,628. On average, Catherine trades about 4,332 units every 75 days since 2020. As of 31 January 2023 he still owns at least 1,618 units of Quotient Ltd stock.
You can see the complete history of Catherine Larue stock trades at the bottom of the page.
Dr. Catherine Larue Ph.D. has been appointed as Independent Director of the Company effective 9/1/2020. She serves as Director of External Affairs at the Integrated Biobank of Luxemburg (IBBL), which is organized within the Luxemburg Institute of Health (LIH) and dedicated to supporting biomedical research, providing biospecimen and biobanking services and infrastructure for applied medical research. Dr. Catherine Larue began her career at Sanofi in the cardiovascular R&D department before joining Sanofi Diagnostics Pasteur in Minneapolis, Minnesota, where she was responsible for assay development on the Access instrument in the immunodiagnostic area. Dr. Larue also served as a Director of business unit at Bio-Rad Laboratories, Inc., and Executive Vice President of Biomarkers at GENFIT, before serving as CEO of IBBL. Dr. Larue has authored 87 publications (h index 19) and filed 13 patents, while also creating and chairing the “Biomarkers Group” in the Competitiveness Bio-cluster (Medicen, Paris). She sits on the boards of Fondation ARC, an organization of public utility focused on cancer research, Genfit a biopharmaceutical company, and Information Technology for Translational Medicine (ITTM S.A.), a clinical data processing company. Dr. Larue holds a Ph.D. in immunology from the University of Rouen and a Master in Business Administration from St. John’s University and ISM Paris.
Catherine Larue is 64, he's been the Independent Director of Quotient Ltd since 2020. There are 4 older and 10 younger executives at Quotient Ltd. The oldest executive at Quotient Ltd is John Wilkerson, 77, who is the Independent Director.
Catherine's mailing address filed with the SEC is C/O QUOTIENT LIMITED, BUSINESS PARK, TERRE BONNE, ROUTE DE CRASSIER 13, EYSINS, V8, 1262.
Over the last 11 years, insiders at Quotient Ltd have traded over $5,237,327 worth of Quotient Ltd stock and bought 21,364,813 units worth $72,052,006 . The most active insiders traders include Advisors Llcperceptive Life..., Zubeen Shroff oraz L John Wilkerson. On average, Quotient Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $57,203. The most recent stock trade was executed by Catherine Larue on 31 January 2023, trading 438 units of QTNT stock currently worth $166.
Quotient Ltd executives and other stock owners filed with the SEC include: